Claims for Patent: 10,292,990
✉ Email this page to a colleague
Summary for Patent: 10,292,990
| Title: | Abiraterone steroid formulation |
| Abstract: | A nanoparticulate composition of abiraterone acetate that allows treatment at a lower dose than convention abiraterone acetate formulations is described as in a method of treating prostate cancer by administering the composition together with a glucocorticoid. |
| Inventor(s): | Nemeth; Paul (Philadelphia, PA), Callahan; Matt (Penn Valley, PA), Bosch; H. William (Bryn Mawr, PA), Norret; Marck (Darlington, AU) |
| Assignee: | SUN PHARMA GLOBAL FZE (Sharjah, AE) |
| Application Number: | 15/345,410 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,292,990 |
| Patent Claims: |
1. A method of treating prostate cancer comprising administering methylprednisolone and a daily dose of between 400 and 600 mg of abiraterone acetate, wherein the
abiraterone acetate is in the form of a tablet or a capsule and has a median particle size of 100 nm to 1000 nm on a volume average basis.
2. The method of claim 1 wherein the daily dose of abiraterone acetate is administered as a single dose. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
